NO20100430L - Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr - Google Patents

Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr

Info

Publication number
NO20100430L
NO20100430L NO20100430A NO20100430A NO20100430L NO 20100430 L NO20100430 L NO 20100430L NO 20100430 A NO20100430 A NO 20100430A NO 20100430 A NO20100430 A NO 20100430A NO 20100430 L NO20100430 L NO 20100430L
Authority
NO
Norway
Prior art keywords
alter
ability
directed
compound
phosphorylation
Prior art date
Application number
NO20100430A
Other languages
English (en)
Inventor
Cesare Mondadori
Fernando Camacho
George Keesler
Zhengbin Yao
Original Assignee
Aventis Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20100430L publication Critical patent/NO20100430L/no
Application filed by Aventis Holdings Inc filed Critical Aventis Holdings Inc

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Fremgangsmåter for å identifisere testforbindelser som endrer cirkadiske rytmer hos pattedyr og mer spesielt, fremgangsmåter for å bestemme en testforbindelses evne til å endre hCK1?- og -?-fosforylering av et humant periodeprotein. Oppfinnelsen angår også en fremgangsmåte for å bestemme en testforbindelses evne til selektivt å endre fosforylering, interagere med eller alternativt degradere en eller flere humane periodeproteiner i forhold til dens evne til å endre fosforylering, interagere med eller alternativt degradere et forskjellig humant periodeprotein.
NO20100430A 1999-06-08 2010-03-23 Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr NO20100430L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32774599A 1999-06-08 1999-06-08
PCT/US2000/015633 WO2000075669A1 (en) 1999-06-08 2000-06-07 Screening methods for altering circadian rhythm proteins

Publications (1)

Publication Number Publication Date
NO20100430L true NO20100430L (no) 2002-02-05

Family

ID=23277866

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20015972A NO330241B1 (no) 1999-06-08 2001-12-06 Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1)
NO20100430A NO20100430L (no) 1999-06-08 2010-03-23 Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr
NO20100431A NO20100431L (no) 1999-06-08 2010-03-23 Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20015972A NO330241B1 (no) 1999-06-08 2001-12-06 Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1)

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20100431A NO20100431L (no) 1999-06-08 2010-03-23 Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)

Country Status (15)

Country Link
US (1) US6555328B1 (no)
EP (1) EP1183541B1 (no)
JP (1) JP4583682B2 (no)
KR (1) KR100722176B1 (no)
AT (1) ATE322016T1 (no)
AU (1) AU767800B2 (no)
BR (1) BR0011437A (no)
CA (1) CA2375450C (no)
DE (1) DE60026998T2 (no)
IL (2) IL146729A0 (no)
MX (1) MXPA01011417A (no)
NO (3) NO330241B1 (no)
NZ (1) NZ514603A (no)
WO (1) WO2000075669A1 (no)
ZA (1) ZA200108962B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476188B1 (en) 1998-06-19 2002-11-05 The Rockefeller University Clock gene and methods of use thereof
US6436628B1 (en) 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
NZ514603A (en) * 1999-06-08 2003-10-31 Aventis Pharma Inc Test compounds that alter the ability of human casein kinase 1 delta and/or epsilon to phosphorylate the human clock proteins
ATE432354T1 (de) * 1999-11-18 2009-06-15 Mitsubishi Tanabe Pharma Corp Transgene säugetiere mit einem period 1 promotor, der rhythmische expression verleiht
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
AU2002248338A1 (en) * 2001-01-11 2002-07-24 University Of Utah Research Foundation Identification of an advanced sleep phase syndrome gene in humans
AU2003278333A1 (en) * 2002-10-25 2004-05-13 University Of Surrey Polymorphism in the per3 gene as a indicator in the diagnosis and treatment of circadian rhythm sleep disorders
EP1576133A2 (en) * 2002-11-27 2005-09-21 University of Utah Research Foundation Casein kinase i epsilon and casein kinase i delta and sleep in humans
ES2334927T3 (es) * 2004-08-19 2010-03-17 Aventis Pharmaceuticals Inc. Derivados de 3-ariltioindol-2-carboxamida y sus analogos como imhibidores de caseina quinasa i.
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
JO2724B1 (en) * 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
WO2007139229A1 (en) * 2006-05-31 2007-12-06 National Institute Of Radiological Sciences Light-inducible and rhythmically expressed genes and method for screening substances that affect an internal clock system
EP2077838B1 (en) * 2006-10-25 2013-04-03 The Rockefeller University Methods for the treatment of amyloid-beta related disorders and compositions therefor
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
CN105744948B (zh) * 2013-10-14 2020-03-24 南京大学 进食节律提前综合征的识别方法及其应用
KR101600144B1 (ko) 2013-12-20 2016-03-04 서울대학교산학협력단 일주기 리듬 수면장애 및 시차 부적응에 대한 예방 또는 치료제 스크리닝 방법
US9944648B2 (en) 2014-01-09 2018-04-17 Intra-Cellular Therapies, Inc. Organic compounds
US11116754B2 (en) 2015-11-13 2021-09-14 The Trustees Of Columbia University In The City Of New York Inhibition of TOR complex 2 increases immunity against bacterial infection
WO2023129377A1 (en) * 2022-01-03 2023-07-06 The Johns Hopkins University Methods and materials for treating heart attack

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1157137A (ja) * 1997-08-28 1999-03-02 Sanyo Bussan Kk 遊技機用特別図柄表示装置
KR100246893B1 (ko) * 1997-12-29 2000-05-01 윤종용 전자렌지용 도어
AU3976099A (en) * 1998-05-07 1999-11-23 President & Fellows Of Harvard College, The Compositions and methods involving regulation of mammalian circadian rhythms
NZ514603A (en) * 1999-06-08 2003-10-31 Aventis Pharma Inc Test compounds that alter the ability of human casein kinase 1 delta and/or epsilon to phosphorylate the human clock proteins

Also Published As

Publication number Publication date
BR0011437A (pt) 2002-03-05
CA2375450A1 (en) 2000-12-14
CA2375450C (en) 2009-04-28
NO20015972L (no) 2002-02-05
IL146729A (en) 2007-06-17
AU5468900A (en) 2000-12-28
JP2003501074A (ja) 2003-01-14
AU767800B2 (en) 2003-11-27
KR100722176B1 (ko) 2007-05-29
EP1183541A1 (en) 2002-03-06
EP1183541B1 (en) 2006-03-29
ATE322016T1 (de) 2006-04-15
NO20100431L (no) 2002-02-05
ZA200108962B (en) 2003-01-30
NO20015972D0 (no) 2001-12-06
WO2000075669A1 (en) 2000-12-14
NO330241B1 (no) 2011-03-14
DE60026998T2 (de) 2007-04-05
DE60026998D1 (de) 2006-05-18
IL146729A0 (en) 2002-07-25
NZ514603A (en) 2003-10-31
US6555328B1 (en) 2003-04-29
MXPA01011417A (es) 2002-06-04
JP4583682B2 (ja) 2010-11-17
KR20020033101A (ko) 2002-05-04

Similar Documents

Publication Publication Date Title
NO20100430L (no) Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
CY1110679T1 (el) Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
EA200200208A1 (ru) Синергитическая композиция
HUP0102511A2 (hu) Kombinált gyógykezelés bipoláris betegségek kezelésére
NO20010882D0 (no) Terapier for behandling av lungesykdommer
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
EA200401070A1 (ru) Способы лечения сосудистых заболеваний
CY1106122T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση της νοσου ευepεθιστου εντερου
EA200500782A1 (ru) Лечение геморрагического шока
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
EA199800690A1 (ru) Замещенные n-[(аминоиминометил)фенилалкил]азагетероцикламиды сульфоновых кислот
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
CY1105380T1 (el) Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων
NO973531L (no) Anvendelse av melatonin for behandling av pasienter som lider av medikamentavhengighet
DE60007548D1 (de) Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
FR2860234B1 (fr) Nouveaux derives 666 du thioxylose

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application